Advanced search
Publication Cover
Acta Cardiologica Volume 70, 2015 - Issue 4
Submit an article Journal homepage
24
Views
10
CrossRef citations to date
0
Altmetric
Articles

Ventricular assist devices in patients with chemotherapy-induced cardiomyopathy: new modalities

Omer Ali SayinClinic for Thoracic and Cardiovascular Surgery, Heart and Diabetes Center, NRW Ruhr University of Bochum, GermanyCorrespondence[email protected]
, MD,
Cenk OzpekerClinic for Thoracic and Cardiovascular Surgery, Heart and Diabetes Center, NRW Ruhr University of Bochum, Germany
, MD,
Michael SchoenbrodtClinic for Thoracic and Cardiovascular Surgery, Heart and Diabetes Center, NRW Ruhr University of Bochum, Germany
, MD,
Fahrettin OzDept. of Cardiology, School of Medicine, Istanbul University, Istanbul, Turkey.
, MD,
Jochen BorgermannClinic for Thoracic and Cardiovascular Surgery, Heart and Diabetes Center, NRW Ruhr University of Bochum, Germany
, MD, PhD,
Jan GummertClinic for Thoracic and Cardiovascular Surgery, Heart and Diabetes Center, NRW Ruhr University of Bochum, Germany
, MD &
Michiel MorshuisClinic for Thoracic and Cardiovascular Surgery, Heart and Diabetes Center, NRW Ruhr University of Bochum, Germany
, MD show all
Pages 430-434 | Received 26 Jul 2014, Accepted 20 Apr 2015, Published online: 23 May 2017

References

  • Combes M, Roney S, De Backer T. Cardiovascular toxicity of cancer treatment. Acta Clin Belg 2011; 66:260–6.
  • Gharib MI, BurnettAK. Chemotherapy induced cardiotoxicity: current practice and prospects of prophylaxis. Eur J Heart Fail 2002; 4:235–42.
  • Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G, Rubino M, Veglia F, Fiorentini C, Cipolla CM. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am CollCardiol 2010; 55: 213–20.
  • Simmons A, Vacek JL, Meyers D. Anthracycline-induced cardiomyopathy. Postgrad Med 2008; 120: 67–72.
  • Khan N, Husain SA, Husain SI, Khalaf N, George J, Raissi F, Segura AM, Kar B, Bogaev RC, Frazier OH. Remission of chronic anthracycline-induced heart failure with support from a continuous-flow left ventricular assist device. Tex Heart lnst J 2012; 39: 554–6.
  • Stewart GC1, Stevenson LW. Keeping left ventricular assist device acceleration on track. Circulation 2011; 123: 1559–68
  • Chatterjee K, Zhang J, Honbo N, KarlinerJS. Doxorubicin cardiomyopathy. Cardiology 2010; 115:155–62.
  • Garbade J, Bittner HB, Barten MJ, Mohr FW. Current trends in implantable left ventricular assist devices. Cardiol Res Pract 2011; 290561.
  • Mehra MR1, Kobashigawa J, Starling R, Russell S, Uber PA, ParameshwarJ, Mohacsi P. Augustine S, Aaronson K, Barr MJ. Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates--2006. Heart Lung Transplant 2006; 25: 1024–42.
  • Appel JM, Sander K, Hansen PB, MøllerJE, Krarup-Hansen A, Gustafsson F. Left ventricular assist device as bridge to recovery for anthracycline induced terminal heart failure. Congest Heart Fail 2012; 18: 291–4.
  • Kurihara C, Nishimura T, Nawata K, Kinosh-ita O, Hisagi M, Motomura N, Kyo S, Ono M. Successful bridge to recovery with VAD implantation for anthracycline-induced cardiomyopathy. J Artif Organs 2011; 14:249–52.
  • LahporJ, Khaghani A, Hetzer R, Pavie A, Friedrich I, Sander K, Striiber M. European results with a continuous-flow ventricular assist device for advanced heart-failure patients. Eur J Cardiothorac Surg 2010; 37: 357–61.
  • Goldstein DJ, Naftel D, Holman W, Bellum-konda L, Pamboukian SV, Pagani FD, Kirklin J. Continuous-flow devices and percutane-ous site infections: clinical outcomes. J Heart Lung Transplant 2012; 31: 1151–7.
  • John R, Kamdar F, Eckman P. Colvin-Adams M, Boyle A, Shumway S, Joyce L, Liao K. Lessons learned from experience with over 100 consecutive HeartMate II left ventricular assist devices. Ann Thorac Surg 2011; 92: 1593–9.
  • John R, Kamdar F, Liao K, Colvin-Adams M, Boyle A, Joyce L. Improved survival and decreasing incidence of adverse events with the HeartMate II left ventricular assist device as bridge-to-transplant therapy. Ann Thorac Surg 2008; 86: 1227–34.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

A worldwide pioneer in biotechnology.
Bristol Myers Squibb – symposium on hypertrophic cardiomyopathy.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.